We wish to develop a protocol for PET/CT examination of humans using the bile acid tracer 11C-cholylsarcosine. This is done by a series of PET/CT examinations of healthy humans and patients with cholestatic disorders.

Examine the effect of ICG on the kinetics of the hepatic transport of 11C-CSar. If no effect is seen on the kinetics, ICG will be used during the "infusion method" experiments.

Drug: 11C-CSar

PET/CT recording with bile acid tracer 11C-cholylsarcosine used to evaluate the transport of bile acids.

Other Name: 11C-cholylsarcosine

Drug: ICG

Infusion of indocyanine green prior and during the PET/CT scanning with the bile tracer 11C-CSar.

Other Name: indocyanine green

Experimental: Infusion method

Determine wether bolus or constant infusion of 11C-CSar is optimal for the PET/CT scanning. If ICG does not affect the kinetics of 11C-CSar it will be used during these experiments to calculate hepatic blood flow.

Drug: 11C-CSar

PET/CT recording with bile acid tracer 11C-cholylsarcosine used to evaluate the transport of bile acids.

Other Name: 11C-cholylsarcosine

Drug: ICG

Infusion of indocyanine green prior and during the PET/CT scanning with the bile tracer 11C-CSar.

Other Name: indocyanine green

Detailed Description:

The purpose of the study is the development of PET/CT protocols using 11C-CSar for human use. PET/CT methods developed in the pig studies are translated to studies in healthy humans and patients with cholestatic disorders. Dynamic PET/CT scans of the liver and biliary system are combined with measurements of tracer concentrations in a radial artery and a liver vein and measurements of hepatic blood flow by intravenous infusion of indocyanine green (ICG)/Ficks principle. Kinetic parameters from PET/CT measurements and invasive measurements are compared for validation of the PET estimated parameters and refinement of the PET modeling, if required.

Eligibility

Ages Eligible for Study:

18 Years and older (Adult, Senior)

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:

Yes

Criteria

Inclusion Criteria:

Patients with cholestatic disorders and healthy subjects

Exclusion Criteria:

Body weight above 110 kg (catheterization problematic).

Diabetes

Pregnant or breast feeding women.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01879735